Although FGFR2 amplification and overexpression are rare in colorectal cancer, our in vitro and in vivo models suggest that emerging FGFR inhibitors could have efficacy in a subset of colorectal cancer harboring this amplification. The gene discussed is FGFR2; the disease is colorectal cancer.